Emerging advances in P-glycoprotein inhibitory nanomaterials for drug delivery

被引:48
|
作者
Kou, Longfa [1 ,2 ]
Sun, Rui [1 ,2 ]
Bhutia, Yangzom D. [3 ]
Yao, Qing [4 ]
Chen, Ruijie [1 ,2 ]
机构
[1] Wenzhou Med Univ, Dept Pharm, Affiliated Hosp 2, Wenzhou, Zhejiang, Peoples R China
[2] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Zhejiang, Peoples R China
[3] Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, Lubbock, TX 79430 USA
[4] Wenzhou Med Univ, Sch Pharmaceut Sci, Dept Pharmaceut, Wenzhou, Zhejiang, Peoples R China
基金
中国国家自然科学基金;
关键词
Multidrug resistance; chemotherapy; P-glycoprotein inhibitor; nanomaterials; drug delivery; VITAMIN-E TPGS; PLURONIC((R)) BLOCK-COPOLYMERS; POLYETHYLENE-GLYCOL SUCCINATE; TARGETED CO-DELIVERY; MULTIDRUG-RESISTANCE; IN-VITRO; MIXED MICELLES; BIOMEDICAL APPLICATIONS; LOADED NANOPARTICLES; FE3O4; NANOPARTICLES;
D O I
10.1080/17425247.2018.1517749
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: P-glycoprotein 1 (P-gp) pumps out many foreign/toxic substances out of the cells, including intracellular drugs, causing multidrug resistance (MDR) and chemotherapy failure. It remains quite a challenge to inhibit P-gp to combat MDR and improve cellular bioavailability since it requires efficient inhibitors along with adequate formulation strategy. Lately, nanocarriers are gaining much attention and form an attractive platform for delivering drugs into cells. Therefore, nanomaterials act as direct inhibitors of P-gp will be an attractive alternative to overcome MDR. Area covered: This paper reviews the most recent advances on those nanomaterials that are currently in the developmental stage and has proven useful to treat P-gp involved MDR. Also, we emphasize those emerging multifunctional nanomaterials that can construct "smart' carriers for both tumor targeting and P-gp inhibition. Furthermore, the mechanisms behind P-gp inhibition and the nanoformulation strategies for drug delivery are also discussed. Expert opinion: In light of these updated reports, this review here seeks to suggest an alternative for the chemoresistant cases, and also bring about new thoughts on tackling P-gp concerned drug delivery issues. New advances in nanomaterials with P-gp inhibition are expected to broaden nanopharmaceutics and traditional chemotherapy applications in the coming years.
引用
收藏
页码:869 / 879
页数:11
相关论文
共 50 条
  • [31] Computer Evaluation of Drug Interactions with P-Glycoprotein
    Lagunin, A. A.
    Gloriozova, T. A.
    Dmitriev, A. V.
    Volgina, N. E.
    Poroikov, V. V.
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2013, 154 (04) : 521 - 524
  • [32] Advances in Studies of P-Glycoprotein and Its Expression Regulators
    Yano, Kentaro
    Tomono, Takumi
    Ogihara, Takuo
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2018, 41 (01) : 11 - 19
  • [33] Computer Evaluation of Drug Interactions with P-Glycoprotein
    A. A. Lagunin
    T. A. Gloriozova
    A. V. Dmitriev
    N. E. Volgina
    V. V. Poroikov
    Bulletin of Experimental Biology and Medicine, 2013, 154 : 521 - 524
  • [34] Identification of drug interaction sites in P-glycoprotein
    Greenberger, LM
    ABC TRANSPORTERS: BIOCHEMICAL, CELLULAR, AND MOLECULAR ASPECTS, 1998, 292 : 307 - 317
  • [35] Role of P-glycoprotein in statin drug interactions
    Holtzman, Carol W.
    Wiggins, Barbara S.
    Spinler, Sarah A.
    PHARMACOTHERAPY, 2006, 26 (11): : 1601 - 1607
  • [36] Clinical relevance of P-glycoprotein in drug therapy
    Lin, JH
    Yamazaki, M
    DRUG METABOLISM REVIEWS, 2003, 35 (04) : 417 - 454
  • [37] P-glycoprotein and drug therapy in organ transplantation
    Lo, A
    Burckart, GJ
    JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 39 (10): : 995 - 1005
  • [38] New Insight into P-Glycoprotein as a Drug Target
    Breier, Albert
    Gibalova, Lenka
    Seres, Mario
    Barancik, Miroslav
    Sulova, Zdenka
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2013, 13 (01) : 159 - 170
  • [39] ADVANCES IN DRUG DELIVERY - TRANSDERMAL DRUG DELIVERY - THE GROUND RULES ARE EMERGING
    GUY, RH
    HADGRAFT, J
    PHARMACY INTERNATIONAL, 1985, 6 (05): : 112 - 116
  • [40] The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions
    Yu, DK
    JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 39 (12): : 1203 - 1211